Hai Gang Chen

Suzhou Sinovent Pharmaceutical Technology Co. Ltd. is a private company that focuses on researching, developing, producing, and commercializing therapeutic drugs. The company is based in Suzhou, China.

Shanghai Weishen Pharmaceutical Co., Ltd. is a company founded in 2019 that specializes in the research, development, production, sale, and service of pharmaceutical machinery. The company is based in Shanghai, China. The Chinese company focuses on scientific and technological innovation to serve the pharmaceutical industry with advanced technology. The company has a professional installation team with a minimum of 6 years of experience, possessing strong practical hands-on problem-solving capabilities. The company aims to improve the production standard and maximize investment benefits through effective training.

Bellen Chemistry Co., Ltd. provides contract chemistry services. It offers chemical synthesis contract development and manufacturing organization (CDMO) services, chemical synthesis contract research organization (CRO) services, and drug molecular building blocks. The company was founded by Bo Liu, Li Xin Xing, Jian Hua Ren, Jian Xun Liu, and Yong Jun Jiang on January 28, 2010 and is headquartered in Beijing, China.

Part of Hepagene Therapeutics, Inc., Yatra Pharmaceutical Technology (Shanghai) Co., Ltd. is a Chinese company that engages in research and development of new drugs. The private company is based in Shanghai, China. The company was founded in 2016 by Xiao Dong Xu.

China International Capital Corp. Ltd. (Broker) (CICC) is the brokerage division of China International Capital Corp. Ltd. which was established in 1995 as a strategic partnership between Chinese and international financial institutions and corporations. Headquartered in Beijing, CICC was the first joint venture investment bank in China. The firm's core business departments were investment banking, capital markets, sales & trading, research, fixed-income and asset management. CICC offers a range of brokerage services to international and domestic institutional and individual investors. In 2007 the firm set up a wholly-owned subsidiary specializing in private equity investments and focusing on buyout opportunities within China.